30 results
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
participation or engagement in any Competing Business; provided, however, that nothing herein shall (A) preclude Seller or its Affiliates from owning five
424B3
CHRS
Coherus Biosciences Inc
26 Jul 23
Prospectus supplement
4:59pm
familiarity with clinical-stage companies like Surface. Based on these considerations, the Surface board of directors authorized the engagement … into an engagement letter, dated February 26, 2023, between Surface and Wedbush. See “—Opinion of Surface’s Financial Advisor” for further information regarding
S-4/A
CHRS
Coherus Biosciences Inc
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
, the Surface board of directors authorized the engagement of Wedbush to serve as Surface’s financial advisor in connection with a potential strategic … transaction or reverse merger and Surface’s entry into an engagement letter, dated February 26, 2023, between Surface and Wedbush. See “—Opinion of Surface’s
S-4
5pypp9kzfsqbczfe
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
ox4fn5
16 Jun 23
Business combination disclosure
8:08am
425
1nbn12essckgwqz
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
7vz 637v7v
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-3.1
c0t6ujffnt600rer
18 Nov 20
Departure of Directors or Certain Officers
4:06pm
10-K
xhaayl23nvs9kh201k0t
23 Mar 15
Annual report
12:00am